Matthew W. Foehr has not been actively trading shares of Ligand Pharmaceuticals in the last ninety days. Most recently, on Friday, May 13th, Matthew W. Foehr bought 2,500 shares of Ligand Pharmaceuticals stock. The stock was acquired at an average cost of $82.76 per share, with a total value of $206,900.00. Following the completion of the transaction, the chief operating officer now directly owns 173,354 shares of the company's stock, valued at $14,346,777.04. Learn More on Matthew W. Foehr's trading history.